Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Elfarr

Urology Athens, TX Medical Doctor

NPI 1275542144 CMS profile 238888

1701 South Palestine, Suite A, Athens, TX 75751

Open in the dashboard

General payments

$3,998

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Elfarr of Athens, TX is reported in the CMS Open Payments database as having received $3,998 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369 18
2024 General $524 25
2023 General $703 38
2022 General $1,359 40
2021 General $367 19
2020 General $316 19
2019 General $360 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Elfarr
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to William Elfarr were reported at $369. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year William Elfarr Urology median Middle half National median
2019 $360 $480 $147–$1,201 $163
2020 $316 $246 $87–$645 $114
2021 $367 $358 $111–$1,000 $132
2022 $1,359 $476 $143–$1,263 $149
2023 $703 $560 $168–$1,461 $160
2024 $524 $563 $170–$1,464 $164
2025 $369 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teleflex LLC $796 9 payments
  2. Astellas Pharma US Inc $632 34 payments
  3. Boston Scientific Corporation $301 14 payments
  4. Antares Pharma, Inc. $281 15 payments
  5. Sumitomo Pharma America, Inc. $243 16 payments
  6. Pfizer Inc. $203 13 payments
  7. PROCEPT BioRobotics Corporation $193 7 payments
  8. Myovant Sciences Inc. $128 7 payments
  9. Urovant Sciences Inc $122 8 payments
  10. Axonics Modulation Technologies, Inc. $117 7 payments
  11. Other $982 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,467 173 payments
  2. Travel and Lodging $446 3 payments
  3. Education $85 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $545 33 payments
  2. UroLift System $498 5 payments
  3. MYRBETRIQ $312 19 payments
  4. UROLIFT $298 4 payments
  5. XYOSTED $281 15 payments
  6. GEMTESA $272 19 payments
  7. ORGOVYX Hormone Therapy $222 12 payments
  8. ORGOVYX Oncology $157 10 payments
  9. AQUABEAM ROBOTIC SYSTEM $153 5 payments
  10. ERLEADA $89 4 payments
  11. Other $1,645 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

3,350

Median for Urology: 1,053

Drug cost

$874,357

Median for Urology: $101,464

Branded share of claims

26%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 34 $483,217
Myrbetriq Mirabegron Brand 303 $239,348
Gemtesa Vibegron Brand 76 $67,376
Mirabegron Er Mirabegron Brand 34 $23,904
Tamsulosin Hcl Generic 1,201 $16,931
Solifenacin Succinate Generic 254 $13,659
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 175 $8,414
Tolterodine Tartrate Er Tolterodine Tartrate Brand 18 $2,516
Estradiol Generic 29 $2,451
Finasteride Generic 207 $2,311

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$357,325

Of which drugs: $32,054

Medicare patients

939

Average age 76

Services billed

26,962

242 women, 697 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 36%
Diabetes 35%
Chronic kidney disease 34%
Cancer 26%
Atrial fibrillation 23%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 26 198 $27,931
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 42 4,301 $463
Injection, testosterone cypionate, 1 mg J1071 Office 11 15,602 $170

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYOSTED
  • Antares Pharma, Inc. $220
$220 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $66
$66 — —
XTANDI
  • Astellas Pharma US Inc $17
  • PFIZER INC. $13
$30 34 —
XIAFLEX
  • Endo USA, Inc. $24
$24 — —
MYRBETRIQ
  • Astellas Pharma US Inc $18
$18 303 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record